Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

Expert Opinion on Drug Safety

Volumn 13, Issue 3, 2014, Pages 351-360

  Perez Lloret, Santiago ^a   Rey, María Verónica ^a   Crispo, James ^b   Krewski, Daniel ^b   Lapeyre Mestre, Marise ^a   Montastruc, Jean Louis ^a   Rascol, Olivier ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adverse drug reactions; Cardiovascular events; Dopamine agonists; Heart failure; Parkinson's disease; Pharmacovigilance; Pramipexole

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIURETIC AGENT; DOMPERIDONE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; NORADRENALIN; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

CARDIOVASCULAR EFFECT; CASE CONTROL STUDY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DOG; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EXOCYTOSIS; HEART FAILURE; HEART MUSCLE FIBROSIS; HOSPITALIZATION; HUMAN; MONOTHERAPY; NATRIURESIS; NONHUMAN; NORADRENALIN RELEASE; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VASODILATATION;

CASE-CONTROL STUDIES; DOPAMINE AGONISTS; HEART FAILURE; HUMANS; PARKINSON DISEASE;

EID: 84896736801     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.888057     Document Type: Review

References (61)

1. Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 1998;4:59-60
2. Nutt JG. Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 1990;40:340-5
3. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003;53(Suppl 3):S3-12
4. Calne DB, Teychenne PF, Leigh PN, et al. Treatment of parkinsonism with bromocriptine. Lancet 1974;2:1355-6
5. U.S. Drug and Food Administration. FDA Announces Voluntary Withdrawal of Pergolide Products. 2007. Available from: Http://www.fda. gov/newsevents/ newsroom/ pressannouncements/2007/ucm108877. htm [Last accessed 17 September 2013]
6. Health Canada. Cease Sale of Permax (pergolide mesylate) in Canada as of August 30, 2007 - For Health Professionals. 2007. Available from: Http://www.healthycanadians.gc.ca/recallalert- rappel-avis/hc-sc/2007/14469a- eng. php [Last accessed 17 September 2013]
7. European Medicines Agency. Questions and Answers on the review of ergot-derived dopamine agonists. 2008. Available from: Http://www.ema. europa.eu/docs/enGB/documentlibrary/ Referralsdocument/ Ergotderiveddopamineagonists31/ WC500011445.pdf [Last accessed 17 September 2013]
8. Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs 2010;24:941-689
9. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80
10. Administration US FAD. FDA Drug Safety Communication: Ongoing safety review of Parkinson's drug Mirapex (pramipexole) and possible risk of heart failure. 2012. Available from: Http://www.fda.gov/Drugs/DrugSafety/ ucm319779.htm [Last accessed 10 September 2013]
11. Emilien G, Maloteaux JM, Geurts M, et al. Dopamine receptors- physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-56
12. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-78
13. Taber KH, Black DN, Porrino LJ, et al. Neuroanatomy of dopamine: Reward and addiction. J Neuropsychiatry Clin Neurosci 2012;24:1-4
14. Pazo JH, Belforte JE. Basal ganglia and functions of the autonomic nervous system. Cell Mol Neurobiol 2002;22:645-54
15. Yeh TL, Yang YK, Chiu NT, et al. Correlation between striatal dopamine D2/D3 receptor binding and cardiovascular activity in healthy subjects. Am J Hypertens 2006;19:964-9
16. Gonzalez-Iglesias AE, Murano T, Li S, et al. Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways. Endocrinology 2008;149:1470-9
17. Manku MS, Horrobin DF, Zinner H, et al. Dopamine enhances the action of prolactin on rat blood vessels. Implications for dopamine effects on plasma prolactin. Endocrinology 1977;101:1343-5
18. Molinari C, Grossini E, Mary DA, et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007;148:4080-90
19. Stamatelopoulos KS, Georgiopoulos GA, Sfikakis PP, et al. Pilot study of circulating prolactin levels and endothelial function in men with hypertension. Am J Hypertens 2011;24:569-73
20. Polakowski JS, Segreti JA, Cox BF, et al. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol 2004;31:837-41
21. Zeng C, Zhang M, Asico LD, et al. The dopaminergic system in hypertension. Clin Sci (Lond) 2007;112:583-97
22. Gomez Mde J, Rousseau G, Nadeau R, et al. Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart. Can J Physiol Pharmacol 2002;80:578-87
23. Nakayama H, Nakayama T, Carnes CA, et al. Electrophysiologic and hemodynamic effects of apomorphine in dogs. Toxicol Appl Pharmacol 2001;177:157-61
24. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 1998;32:187-97
25. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: From structure to function. Physiol Rev 1998;78:189-225
26. Manrique-Maldonado G, Gonzalez-Hernandez A, Marichal-Cancino BA, et al. The dopamine receptors mediating inhibition of the sympathetic vasopressor outflow in pithed rats: Pharmacological correlation with the D(2) -like type. Basic Clin Pharmacol Toxicol 2011;109:506-12
27. Garcia-Tornadu I, Ornstein AM, Chamson-Reig A, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010;151:1441-50
28. Garcia-Tornadu I, Perez-Millan MI, Recouvreux V, et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse. Neuroendocrinology 2010;92:207-14
29. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-8
30. Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc 2012;1:e002279
31. Zarei S, Frieden M, Rubi B, et al. Dopamine modulates von Willebrand factor secretion in endothelial cells via D2-D4 receptors. J Thromb Haemost 2006;4:1588-95
32. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998;21:141-51
33. Tulloch IF. Pharmacologic profile of ropinirole: A nonergoline dopamine agonist. Neurology 1997;49:S58-62
34. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs 1998;55(Suppl 1):10-16
35. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-93
36. Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44
37. Gyires K, Zadori ZS, Torok T, et al. alpha(2)-Adrenoceptor subtypes-mediated physiological, pharmacological actions. Neurochem Int 2009;55:447-53
38. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)- adrenergic receptor subtype diversity: One receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002;283:R287-95
39. Franchi F, Lazzeri C, Barletta G, et al. Centrally mediated effects of bromocriptine on cardiac sympathovagal balance. Hypertension 2001;38:123-9
40. Quinn N, Illas A, Lhermitte F, et al. Bromocriptine in Parkinson's disease: A study of cardiovascular effects. J Neurol Neurosurg Psychiatry 1981;44:426-9
41. Durrieu G, Senard JM, Rascol O, et al. Blood pressure and plasma catecholamines in never-treated parkinsonian patients: Effect of a selective D1 agonist (CY 208-243). Neurology 1990;40:707-9
42. Leibowitz M, Lieberman AN, Neophytides A, et al. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease. Adv Neurol 1983;37:121-30
43. Di Giacopo R, Fasano A, Fenici R, et al. Rare and serious cardiac side effects during ropinirole titration. Mov Disord 2010;25:1509-10
44. Rocchi C, Pierantozzi M, Pisani V, et al. The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. Eur Neurol 2012;68:187-92
45. Perez-Lloret S, Bondon-Guitton E, Rascol O, et al. Adverse drug reactions to dopamine agonists: A comparative study in the French Pharmacovigilance Database. Mov Disord 2010;25:1876-80
46. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009;8:929-37
47. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: Absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29:80-6
48. Tan LC, Ng KK, Au WL, et al. Bromocriptine use and myocardial function. Mov Disord 2011;26:923-4
49. Rasmussen VG, Poulsen SH, Dupont E, et al. Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: Systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking. Eur J Echocardiogr 2008;9:803-8
50. Arbouw ME, Movig KL, Guchelaar HJ, et al. Dopamine agonists and ischemic complications in Parkinson's disease: A nested case-control study. Eur J Clin Pharmacol 2012;68:83-8
51. Mokhles MM, Trifiro G, Dieleman JP, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacol Res 2012;65:358-64
52. Hsieh PH, Hsiao FY. Risk of heart failure associated with dopamine agonists: A nested case-control study. Drugs Aging 2013;30(9):739-45
53. Renoux C, Dell'Aniello S, Brophy JM, et al. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf 2012;21:34-41
54. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996-1002
55. Tayebati SK, Lokhandwala MF, Amenta F. Dopamine and vascular dynamics control: Present status and future perspectives. Curr Neurovasc Res 2011;8:246-57
56. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: Old drug, new formulation and new indication. Diabetes Obes Metab 2010;12:1048-57
57. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46
58. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75
59. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7
60. Perez-Lloret S, Rey MV, Ratti L, et al. Pramipexole for the treatment of early Parkinson's disease. Expert Rev Neurother 2011;11:925-35
61. Palazzuoli A, Beltrami M, Ruocco G, et al. The role of natriuretic peptides for the diagnosis of left ventricular dysfunction. ScientificWorldJournal 2013;2013:784670